25th May 2016 08:03
LONDON (Alliance News) - LiDCO Group PLC Wednesday said it continues to expect its current year to be one of rising sales and cash generation, as it saw good growth in sales in its first quarter.
The company, which makes hemodynamic monitoring equipment, said in a statement ahead of its annual general meeting that it had continued to make good progress against the strategy it outlined last October.
"Since the start of the financial year, I have been able to announce the launch of our new LiDCOunity product, renewal of UK sales distribution contract with Argon Medical, registration of our products in China, and the signing of a number of new distribution agreements around the world including in the USA where ICU Medical will sell our LiDCO IM non-invasive hemodynamic monitoring system," said Chief Executive Matt Sassone in the statement.
"In addition, I am pleased to announce that this week, we will be launching our non-invasive offering in Japan at the Annual Japanese Society of Anaesthesia meeting. Japan is the second largest hemodynamic monitoring market globally, launching LiDCOrapid with CNAP gives LiDCO increased product differentiation as we look to gain greater market share in this important market," Sassone added.
Shares in LiDCO were untraded Wednesday morning. They last closed at 7.30 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
LID.L